| Literature DB >> 29884876 |
Luiza Carvalho Mourão1, Rodrigo de Paula Baptista2, Zélia Barbosa de Almeida1, Priscila Grynberg3, Maíra Mazzoni Pucci4, Thiago Castro-Gomes1, Cor Jesus Fernandes Fontes5, Sumit Rathore6, Yagya D Sharma6, Rosiane A da Silva-Pereira4, Marcelo Porto Bemquerer3, Érika Martins Braga7.
Abstract
Clearance of non-infected red blood cells (nRBCs) is one of the main components of anemia associated with Plasmodium vivax malaria. Recently, we have shown that anemic patients with P. vivax infection had elevated levels of anti-RBCs antibodies, which could enhance in vitro phagocytosis of nRBCs and decrease their deformability. Using immunoproteomics, here we characterized erythrocytic antigens that are differentially recognized by autoantibodies from anemic and non-anemic patients with acute vivax malaria. Protein spots exclusively recognized by anemic P. vivax-infected patients were identified by mass spectrometry revealing band 3 and spectrin as the main targets. To confirm this finding, antibody responses against these specific proteins were assessed by ELISA. In addition, an inverse association between hemoglobin and anti-band 3 or anti-spectrin antibodies levels was found. Anemic patients had higher levels of IgG against both band 3 and spectrin than the non-anemic ones. To determine if these autoantibodies were elicited because of molecular mimicry, we used in silico analysis and identified P. vivax proteins that share homology with human RBC proteins such as spectrin, suggesting that infection drives autoimmune responses. These findings suggest that band 3 and spectrin are potential targets of autoantibodies that may be relevant for P. vivax malaria-associated anemia.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29884876 PMCID: PMC5993813 DOI: 10.1038/s41598-018-27109-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Levels of IgG against protein extracts of nRBCs in plasma from P. vivax-infected patients with or without anemia. IgG antibody responses were evaluated by ELISA using plasma from healthy individuals (n = 8) and anemic (n = 24) or non-anemic P. vivax-infected patients (n = 24). Results are shown as values of mean optical density and standard error of the mean. Differences between the groups were determined using Kruskal-Wallis test followed by Dunn post hoc test (p value <0.0001).
Figure 2Representative 2D-SDS-PAGE map of RBC protein spots identified by mass spectrometry. 100 µg of nRBCs protein extract were focused on pH 4–7 IPG strips (7 cm) and then separated by SDS-PAGE 12%. Gel was stained with colloidal Coomassie Blue G-250. The molecular masses (kDa) of the protein standards are indicated on the left. All the protein spots that matched to their corresponding spot in the western blotting were excised from the gel and processed for MALDI-ToF/ToF mass spectrometry analysis. These protein spots are listed in the Supplementary Tables 1 and 2.
Figure 3Comparative analysis of the IgG repertoire against nRBC proteins among subjects with distinct vivax malaria clinical features. The proteins resolved by 2D-SDS-PAGE were blotted onto PVDF membranes and probed with different plasma pools: (A) healthy, (B) patients with vivax malaria and no anemia or (C) P. vivax-infected patients with anemia. Bound antibodies were detected with HRP conjugated anti-human IgG (1:6000) using an ECL chemiluminescence-based kit. Images were analysed using ImageMaster 2D Platinum software (GE). A representative image of three independent experiments is shown. Western blots were cropped for easier visualization; uncropped images are available in the supplemental material. All the protein spots detected in the Western blotting that matched to their corresponding spot in 2D-SDS-PAGE gel were processed for MALDI-ToF/ToF mass spectrometry analysis and are listed in the supplementary Tables 1 and 2.
Figure 4Anti-band 3 and anti-spectrin antibodies correlate with anemia in patients with acute P. vivax infection. Levels of anti-band 3 and anti-spectrin antibodies were detected by ELISA in plasma samples from patients with patent P. vivax infection presenting or not presenting anemia. Antibody levels were expressed as reactivity index (RI), which was calculated as the ratio between the mean OD generated by each test sample and the mean OD plus two standard deviations of samples from eight healthy blood donors never exposed to malaria. RIs equal or greater than 1.0 were scored as positive (A) Anti-band 3 and anti-spectrin antibodies levels were compared between anemic (n = 24) and non-anemic P. vivax-infected patients (n = 24) using Mann-Whitney test. Scatter plots show the means and standard deviations. The dotted lines on each graph represent the threshold above which samples were considered as positive. (B) Heat map of IgG antibody profile against band 3 and spectrin in plasma from anemic and non-anemic patients with vivax malaria. Grey colour indicates that antibody levels are at least greater than the mean plus two standard deviations of the healthy controls whereas white colour denotes the opposite result. Associations between hemoglobin levels and anti-band 3 or anti-spectrin antibodies (C and D, respectively) were analysed by Spearman correlation.
P. vivax proteins mimetic to human proteins.
|
|
|
|
|
|---|---|---|---|
| sp|O60641|AP180_HUMAN | PVX_092010-AA:777 | hypothetical protein, conserved | Clathrin coat assembly protein AP180 |
| sp|O94856|NFASC_HUMAN | PVX_095335-AA:266 | hypothetical protein, conserved | Neurofascin |
| sp|O94988|FA13A_HUMAN | PVX_123250-AA:290 | hypothetical protein, conserved | Protein FAM13A |
| sp|P07205|PGK2_HUMAN | PVX_123515-AA:1081 | MAC/Perforin domain containing protein | Phosphoglycerate kinase 2 |
| sp|P35611|ADDA_HUMAN | PVX_099980-AA:800 | major blood-stage surface antigen Pv200 | Alpha-adducin |
| sp|P55209|NP1L1_HUMAN | PVX_091530-AA:524 | hypothetical protein, conserved | Nucleosome assembly protein 1-like 1 |
| sp|P78356|PI42B_HUMAN | PVX_099150-AA:363 | hypothetical protein, conserved | Phosphatidylinositol 5-phosphate 4-kinase type-2 beta |
| sp|Q12873|CHD3_HUMAN | PVX_093655-AA:1234 | hypothetical protein, conserved | Chromodomain-helicase-DNA-binding protein 3 |
| sp|Q13151|ROA0_HUMAN | PVX_092895-AA:619 | hypothetical protein, conserved | Heterogeneous nuclear ribonucleoprotein A0 |
| sp|Q13637|RAB32_HUMAN | PVX_123100-AA:280 | hypothetical protein, conserved | Ras-related protein Rab-32 |
| sp|Q5S007|LRRK2_HUMAN | PVX_000660-AA:258 | hypothetical protein | Leucine-rich repeat serine/threonine-protein kinase 2 |
| sp|Q6PL18|ATAD2_HUMAN | PVX_101610-AA:137 | RAD protein (Pv-fam-e) | ATPase family AAA domain-containing protein 2 |
| sp|Q6WRI0|IGS10_HUMAN | PVX_085900-AA:1308 | hypothetical protein, conserved | Immunoglobulin superfamily member 10 |
| sp|Q6ZRI8|RHG36_HUMAN | PVX_114675-AA:140 | hypothetical protein, conserved | Rho GTPase-activating protein 36 |
| sp|Q9BQ39|DDX50_HUMAN | PVX_117850-AA:2285 | hypothetical protein, conserved | ATP-dependent RNA helicase DDX50 |
| sp|Q9BYB0|SHAN3_HUMAN | PVX_122920-AA:552 | hypothetical protein, conserved | SH3 and multiple ankyrin repeat domains protein 3 |
| sp|Q9BZF9|UACA_HUMAN | PVX_099150-AA:822 | hypothetical protein, conserved | Uveal autoantigen with coiled-coil domains and ankyrin repeats |
| sp|Q9H254|SPTN4_HUMAN | PVX_003755-AA:415 | hypothetical protein, conserved | Spectrin beta chain, brain 3 |
| sp|Q9H4A3|WNK1_HUMAN | PVX_118355-AA:350 | hypothetical protein | Serine/threonine-protein kinase WNK1 |
| sp|Q9NQC3|RTN4_HUMAN | PVX_099980-AA:809 | major blood-stage surface antigen Pv200 | Reticulon-4 |
| sp|Q9P0M6|H2AW_HUMAN | PVX_083455-AA:988 | hypothetical protein, conserved | Core histone macro-H2A.2 |
| sp|Q9UPE1|SRPK3_HUMAN | PVX_123910-AA:330 | hypothetical protein, conserved | SRSF protein kinase 3 |
| sp|Q9UPN3|MACF1_HUMAN | PVX_099150-AA:569 | hypothetical protein, conserved | Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 |
Plasmodium spectrin-like ortholog sequences.
| Gene | Organism | Product | Length |
|---|---|---|---|
| PBANKA_0304100 | hypothetical protein, conserved | 1030 | |
| PCHAS_0306300 |
| hypothetical protein, conserved | 1027 |
| PCYB_042380 | hypothetical protein, conserved | 840 | |
| PF3D7_0206500 | hypothetical protein, conserved | 1436 | |
| PKNH_0414500 | hypothetical protein, conserved | 1101 | |
| PY17X_0304700 | hypothetical protein, conserved | 983 | |
| PY00070 | hypothetical protein | 958 | |
| PYYM_0305000 | hypothetical protein, conserved | 983 | |
| PVX_003755 | hypothetical protein, conserved | 1085 |
Figure 5Comparison of the divergence of spectrin-like proteins between different Plasmodium species. (A) Plasmodium “spectrin-like” maximum likelihood phylogenetic tree. Two groups are detected: one group containing the Plasmodium falciparum protein (P1) and the other with the P. vivax protein (P2); P1 and P2 represents the two putative phylogenetic groups of spectrin-like sequences between the analyzed Plasmodium species. (B) P. falciparum protein Pf3D7_0206500 synteny alignment against all other Plasmodium species spectrin-like proteins. The figure shows that the C-terminus (red end) is highly conserved in all proteins and the N-terminus (green end) is only conserved in the group B sequences. Only alignments with more than 75% identity were represented in this figure. The conserved C-terminus region among all species is mimetic to the human pleckstrin-like homology domain (PH domain).
Baseline characteristics of the study population.
| Characteristic | |||
|---|---|---|---|
| Age (years) | 29.5 [27.7–41.2] | 30.0 [24.0–42.0] | 0.8954 |
| Number of malaria previous episodes | 2 [1–4] | 3 [0–10] | 0.8895 |
| Parasitemia (parasites/µL) | 7,275 [2,418–12,331] | 2,375 [7,000–16,500] | 0.0517 |
| Hemoglobin (g/dL) | 9.7 [8.4–10.1] | 16.1 [15.4–16.8] | <0.0001 |
| Hematocrit (%) | 28.0 [25.0–29.4] | 46.1 [45.4–48.08] | <0.0001 |
| Platelets (cells/mm3) | 101,000 [69,000–126,000] | 160,500 [112,750–193,250] | 0.0106 |
| Leucocytes (cells/mm3) | 4,900 [3,700–6,000] | 5,390 [4,633–6,313] | 0.2930 |
Values are shown as median and interquartile ranges.